Corcept Therapeutics CORT Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's investing cash flow?
- Corcept Therapeutics (CORT) reported investing cash flow of $4.54M in Q1 2026.
- How has Corcept Therapeutics's investing cash flow changed year-over-year?
- Corcept Therapeutics's investing cash flow increased by 243.2% year-over-year, from -$3.17M to $4.54M.
- What is the long-term trend for Corcept Therapeutics's investing cash flow?
- Over 2 years (2021 to 2024), Corcept Therapeutics's investing cash flow has grown at a 14.2% compound annual growth rate (CAGR), from $136.13M to -$177.6M.
- What does investing cash flow mean?
- The net cash flow from buying or selling long-term assets and investments.
- How do you interpret investing cash flow?
- Negative values often indicate aggressive investment in growth, while positive values may indicate asset sales or divestitures.
- How does investing cash flow compare across companies?
- Highly dependent on the company's current investment cycle and strategic growth phase.